XLO vs. LEXX, CARA, UNCY, VYNE, CASI, EYEN, GANX, SNSE, PMN, and HCWB
Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Lexaria Bioscience (LEXX), Cara Therapeutics (CARA), Unicycive Therapeutics (UNCY), VYNE Therapeutics (VYNE), CASI Pharmaceuticals (CASI), Eyenovia (EYEN), Gain Therapeutics (GANX), Sensei Biotherapeutics (SNSE), ProMIS Neurosciences (PMN), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical preparations" industry.
Lexaria Bioscience (NASDAQ:LEXX) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.
13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 7.6% of Lexaria Bioscience shares are held by insiders. Comparatively, 4.6% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Lexaria Bioscience has higher revenue and earnings than Xilio Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lexaria Bioscience currently has a consensus target price of $12.00, suggesting a potential upside of 280.95%. Given Xilio Therapeutics' higher possible upside, research analysts clearly believe Lexaria Bioscience is more favorable than Xilio Therapeutics.
Lexaria Bioscience has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500.
In the previous week, Xilio Therapeutics had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 3 mentions for Xilio Therapeutics and 2 mentions for Lexaria Bioscience. Xilio Therapeutics' average media sentiment score of 0.46 beat Lexaria Bioscience's score of -0.73 indicating that Lexaria Bioscience is being referred to more favorably in the media.
Xilio Therapeutics' return on equity of -133.97% beat Lexaria Bioscience's return on equity.
Xilio Therapeutics received 9 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 73.33% of users gave Xilio Therapeutics an outperform vote.
Summary
Lexaria Bioscience beats Xilio Therapeutics on 9 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xilio Therapeutics Competitors List
Related Companies and Tools
